New Unique Device Identification requirements have commenced in Australia, beginning with higher-risk medical devices as part of a broader push to improve traceability, recalls and patient safety.
The Therapeutic Goods Administration has begun the phased introduction of Unique Device Identification (UDI) requirements for medical devices supplied in Australia, with the first requirements taking effect from 1 July 2026.
The initial phase applies to higher-risk medical devices, including Class IIb and Class III devices, before expanding to other device classifications over the coming years. According to the TGA, Class IIa, Class Is and in vitro diagnostic devices will follow later as part of the staged national implementation.
The system is designed to make medical devices easier to identify and trace across their lifecycle, giving consumers, healthcare professionals, industry and regulators clearer access to accurate, up-to-date information.
A new layer of device traceability
A UDI is a globally unique identifier applied to a medical device label, packaging and, in some cases, directly to the device itself. The TGA describes it as similar to a barcode, combining numbers, letters and symbols to identify a particular model of device.
The identifier is supported by the Australian UDI Database, known as AusUDID, which will allow users to search device information at no cost. The database is expected to include details such as the device identifier, brand name, manufacturer information, size, clinical characteristics and any related Patient Information Leaflets. Importantly, the TGA states that AusUDID does not store patient information.
In the event of a recall, safety advisory or adverse event, improved device identification can help regulators and healthcare teams more quickly identify affected devices and, where relevant, the patients who may require follow-up.
The TGA’s guidance notes that previous device safety crises, including those involving hip implants, urogynaecological mesh and breast implants, have highlighted the difficulty of efficiently tracking and tracing devices once supplied or implanted. The Australian UDI system has been introduced to strengthen patient safety and improve traceability as part of broader medical device reforms.
What devices are included?
Most medical devices and IVDs supplied in Australia will eventually have a UDI, although the requirements are being introduced by risk classification.
Class III and Class IIb devices are first, with UDI labelling and record submission requirements commencing from 1 July 2026. Class IIa devices follow from 1 July 2027, while Class Is devices follow from 1 July 2028. For IVDs, Class 4 and Class 3 devices have UDI labelling and record submission dates from 1 July 2028, with Class 2 and Class 1 IVDs following from 1 July 2029.
Lower-risk Class I devices, such as non-sterile gauze, face shields and mouthguards, are not required to comply with UDI requirements and will continue to be identified through existing methods.
For reusable devices that are reprocessed between use on different patients, direct marking requirements may also apply. These direct marking milestones begin later, depending on device classification.
Takeaways for aesthetic clinics
The primary compliance burden sits with sponsors and manufacturers, not individual practitioners or clinics, unless a clinic is acting in one of those roles.
Manufacturers are responsible for allocating identifiers, applying UDI-compliant labelling and, where relevant, direct marking. Sponsors are responsible for submitting UDI records to AusUDID, linking those records to Australian Register of Therapeutic Goods inclusions and ensuring the data remains accurate and up to date. The TGA guidance states that UDI records must be submitted to AusUDID within 30 days of supply of the device in Australia.
However, aesthetic medical practices should still be aware of the changes, particularly where they use higher-risk devices, implantable devices or capital equipment, or where device records form part of clinical documentation, consent processes, incident reporting or recall management.
The introduction of UDI may also make Patient Implant Cards more useful for patients. When a medical device is implanted in a hospital or healthcare setting in Australia, patients should be provided with a Patient Implant Card containing key information about the implant, including the UDI. Once included, the UDI can be used to search AusUDID for further details about the device.
For clinics, the immediate step is to understand whether devices used in practice fall within the first phases of the rollout and to confirm how suppliers, distributors and sponsors will provide UDI-related information. Practices may also wish to review how device details are recorded in patient files, how implant information is stored, how recall notifications are managed and how clinical teams would identify affected patients if a device safety issue arises.
The TGA has published detailed guidance for sponsors and manufacturers, including requirements for labelling, packaging, direct marking, UDI triggers, device-specific requirements and AusUDID record submission.
